Tilbake til søkeresultatene

NAERINGSPH-Nærings-phd

Treatment of Non-Hodgkin Lymphoma with 177Lu-HH1/Betalutin

Tildelt: kr 1,9 mill.

-

The main drawback with conventional treatments of disseminated cancer or cancer metastases, such as external beam radiation and chemotherapy, is the lack of cellular specificity. Hence, healthy normal tissue is damaged before curative dosage is obtained. Radioimmunotherapy (RIT), i.e. treatment with radioactively labeled monoclonal antibodies that emits radiation against cancer from within the human body, is emerging as a new modality in cancer therapy. Non-Hodgkins Lymphoma (NHL) is the fifth most common cause of cancer in the United States, with an estimated incidence of 65,540 cases in 2010. B-cell indolent (low-risk group) NHL is not curable with standard treatment. The CD37 antigen is selectively expressed on B-cells and therefore a valuable target f or treatment of cancer that originates from these cells, like NHL but also chronic lymphatic leukemia (CLL). The most common radiopharmaceuticals used in therapy today utilize substances disintegrating with the emission of a beta particle. Beta particles are electrons emitted from the nucleus of an atom, the range in tissue is typically a few millimeters and the total energy deposited is typically 0.5-2 MeV. The millimeter range of beta-particles makes this type of radiation ideal for treatment of larger tumor masses, i.e. Non-Hodgkin Lymphoma that are easily accessible for monoclonal antibodies. The millimeter-range results in cross radiation of tumor tissue that is not accessible by the antibodies. We have made a new radioimmunoconjugate, Betalutin®, ba sed on the HH1 antibody, Lutetium-177 and the chelator DOTA. Professor Øyvind Bruland, Dr. Roy H. Larsen and Dr. Jostein Dahle have now established a company, Nordic Nanovector AS, in order to commercialize Betalutin. The main goal of this industrial PhD is to determine the therapeutic effect of Betalutin.

Budsjettformål:

NAERINGSPH-Nærings-phd